Latest Financial Results
Q2 2019
Quarterly Results
Jun 30, 2019
Sign Up for Email AlertsSign Up Today
Investor Relations
NYSE American Symbol
SYN
Price
Change
Volume
Day Low/High
52 Week Low/High
Analyst Coverage
A.G.P. / Alliance Global PartnersJames Molloy
BTIGTimothy Chiang
Griffin SecuritiesKeith A. Markey, Ph.D., M.B.A.
William Blair & Co.Y. Katherine Xu, Ph.D.
Overview
Synthetic Biologics, Inc. is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead late-stage candidates are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics to prevent microbiome damage, C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company’s preclinical pursuits include an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody therapies for the prevention and treatment of pertussis.
View ProfileLeadership
Our experienced management team holds an extensive clinical and commercial track record.
Investor Relations
Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364
info@syntheticbiologics.com
Transfer Agent
Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
#430
Denver, CO 80209
T: (303) 282-4800